Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma

Zhu, Xiao-feng; Shi, Yuhua; Cheng, Xiao-Duan; Zhao, Cheng-Luo; Wu, Yan

doi:10.1016/j.ygyno.2003.08.038

Cited by 75 publications

(53 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a consequence, multiple immunohistochemical panels have been proposed to help establish the diagnosis [4][5][6][7]. However, because of a lack of sensitivity and specificity, immunohistochemistry has not established itself as diagnostically reliable [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

JAZF1 and JJAZ1 gene fusion in primary extrauterine endometrial stromal sarcoma

et al. 2011

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

JAZF1 and JJAZ1 gene fusion in primary extrauterine endometrial stromal sarcoma

et al. 2011

View full text Add to dashboard Cite

“…Diffuse CD10 immunoreactivity is usually seen in cases of uterine stromal tumors, and it is sometimes useful in differentiating ESS from LMS, even though this antigen should not be used in isolation when analyzing uterine mesenchymal tumors [16,21]. A panel of markers, i.e., CD10, CD44, and h-caldesmon, might be useful in distinguishing ESS from cellular leiomyoma [22].…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers

et al. 2010

View full text Add to dashboard Cite

Uterine sarcomas are rare and aggressive gynecologic malignancies. In this immunohistochemical (IHC) study, expression of Ki-67, p53, CD10, CD44, desmin, smooth muscle actin, estrogen receptor α (ERα), androgen receptor (AR), progesterone receptor A (PRA), and c-kit and their influence on survival in cases of uterine carcinosarcoma (CS), leiomyosarcoma (LMS), and endometrial stromal sarcoma (ESS) were evaluated. Medical records were reviewed and data collected concerning all uterine sarcomas treated during a 12-year period at Helsinki University Central Hospital. There was sufficient histological material for IHC analysis and slide review in 67 cases. Survival analysis was performed using the Kaplan-Meier method, and median survival times with 95% confidence intervals are given. Survival in cases of LMS was statistically significantly affected by the expression of p53, ERα, and PRA. Striking differences in expression of IHC markers when comparing results with those in earlier studies were the absence of AR immunoreactivity in all uterine sarcomas and low incidence of c-kit (15%; in endometrial stromal sarcoma). None of the markers was statistically significantly associated with survival of ESS and CS patients. The expression of p53, ERα, and PRA in uterine LMS may give prognostic information concerning the behavior of the disease. Hormonal therapy could be recommended as a treatment option in cases of hormone receptor-positive LMS.

show abstract

“…Expression of desmin, α SMA, calponin h1, h-caldesmon, estrogen receptor, progesterone receptor, CD10, CD44v3 and proliferating cell nuclear antigen have been studied to differentiate these tumors. 11 It has been shown that a panel of hcaldesmon, CD10 and CD44v3 will distinguish ESS from cellular leiomyoma in most cases. 11 …”

Section: Discussionmentioning

confidence: 99%